HMRC expects to rake in £110 million a year from upcoming inheritance tax changes on AIM shares. The tax relief will be cut ...

We asked our writers to share their best AIM-listed stocks to consider buying, featuring five very different businesses. The ...

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19.

The ‘Jewel in the Crown’ of London’s markets, AIM has been a central feature of UK capital markets for the last 30 years providing growing companies with access to capital and liquidity.

Much like those in a healthy, long-term marriage, two well-established local businesses are celebrating their relationship ...

MaxCyte said it would propose a delisting of its shares on London's AIM to shareholders but will retain its listing on the Nasdaq Global Select Market.